Huawei Weng

Apr 2, 2024 | genomemedicine.biomedcentral.com | Zegeng Chen |He Huang |Huangming Hong |Huageng Huang |Huawei Weng |Le Yu | +6 more

The clinical features of all 163 enrolled patients were examined and a side-by-side comparison among different cohorts was performed. Majority of patients (97.1%, 136 out of 140 patients whose treatment information is accessible) received first-line asparaginase-based chemotherapy. The NODE and ICGC cohorts are mostly comprised of primary patients, whereas the NKT_project and EGA cohorts contain more relapsed/refractory patients (Additional file 2: Table S2).